The Pharmaceutical world and those involved with the manufacture of sterile products are anxiously looking out for the publication of the final approved revision of …

Annex 1 “Manufacture of Sterile Medicinal Products” was first published in 1971 and forms part of EudraLex Volume 4 [1], which interprets the basic principles …

The strategies used to create and maintain strong-pharmaceutical patent portfolios must evolve with developments in the pharmaceutical space. These developments include not just scientific advancements …

The challenge of ensuring healthcare sustainability, the rise in more targeted treatments, and a shift in emphasis to preventative interventions, not to mention the importance …

Companies must safeguard their mature portfolios while continuously innovating and developing new products. But in-house resources are stretched and often lack the broader knowledge needed …

The process of developing a revolutionary medical device from the proof-of-concept stage to the marketing stage is expensive and complicated. The creation of a new …

The application of high throughput screening techniques and computational chemistry has resulted in a marked shift in drug candidates with identified therapeutic potential, increasing the …

Advances in combinatorial chemistry and high-throughput screening continue to introduce poorly water-soluble active ingredient (API) chemistries into pharmaceutical development. For more than 25 years, high-throughput …

Nearly all synthetic steps in industrial chemical manufacturing end with crystallisation. This is because it is almost always the most efficient method to purify and …

Technological advances in drug manufacturing equipment and process optimisation play a significant role in increasing the speed of the clinic of critical biologic drugs. Although …